en · de · es · fr · pt
ghk-cu-notes.peptides6608.com › Topic › Chemical Identity Of Ghk-cu — Research Overview

Chemical Identity Of Ghk-cu — Research Overview

By Editorial Desk · published 2026-06-18 · last reviewed 2026-07-28 · Topic

plasma peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-07-28. Numbers and descriptions here follow the published literature rather than marketing material.

Chemical Identity Of GHK-Cu

The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.

Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.

Biochemical Identity and Discovery

Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.

GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.

The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.

Ghk-cu at a glance

PropertyValueNotes
Chemical classCopper(II) peptide complexPeptide chain coordinated to a single metal ion
CAS number89030-95-5Indexed for the peptide-copper complex
Molecular formulaC14H22CuN6O4Approximate formula for a one-to-one complex
AppearanceBlue to violet solidColor from copper d-d transitions
Solubility classFreely soluble in waterAlso dispersible in some polar solvents

Identity And Molecular Background

The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.

Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.

Related pages on this site

Identity and Biochemical Background

GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.

Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.

Reference notes

For the ninth patient, they introduced a surgical instrument called a leucotome; this was a cannula that was 11 centimetres (4.3 in) in length and 2 centimetres (0.79 in) in diameter. It had a retractable wire loop at one end that, when rotated, produced a 1 centimetre (0.39 in) diameter circular lesion in the white matter of the frontal lobe. Typically, six lesions were cut into each lobe, but, if they were dissatisfied with the results, Lima might perform several procedures, each producing multiple lesions in the left and right frontal lobes. By the conclusion of this first run of leucotomies in February 1936, Moniz and Lima had operated on twenty patients with an average period of one week between each procedure; Moniz published his findings with great haste in March of the same year. The patients were aged between 27 and 62 years of age; twelve were female, and eight were male. Nine of the patients were diagnosed with depression, six with schizophrenia, two with panic disorder, and one each with mania, catatonia and manic-depression. Their most prominent symptoms were anxiety and agitation. The duration of their illness before the procedure varied from as little as four weeks to as much as 22 years, although all but four had been ill for at least one year. Patients were normally operated on the day they arrived at Moniz's clinic and returned within ten days to the Miguel Bombarda Mental Hospital. A perfunctory post-operative follow-up assessment took place anywhere from one to ten weeks following surgery.

=== Naming === The etymology of the current name is rooted in its appearance and habitat. Xanthoria derives from the Greek xănthós, meaning 'yellow', with the generic suffix oria ("pertaining to"), and alludes to the lichen's bright orange-yellow color. The species epithet parietina comes from Latin parietina ('of walls'), referring to its frequent occurrence on walls. Thus, the name Xanthoria parietina essentially means "yellow wall (lichen)", a fitting description of this common orange lichen, and one of its several English common names. Other common names used for this species include "common orange lichen", "yellow scales", "maritime sunburst lichen", "wall lichen", and "shore lichen".

Chattopadhyay, R., & Roy, S.* (2002) J Biol Chem, 277, 33641-7. https://doi.org/10.1074/jbc.M203197200 Effect of phosphorylation on the structure and fold of transactivation domain of p53. Kar S., Sakaguchi, K., Shimohigashi, Y., Samaddar, S., Banerjee, R., Basu, G., Swaminathan, V., Kundu, TK., & Roy, S.* (2002) J Biol Chem, 277, 15579-85. https://doi.org/10.1074/jbc.M106915200 Effect of osmolytes and chaperone-like action of P-protein on folding of nucleocapsid protein of Chandipura virus. Majumder A, Basak S, Raha T, Chowdhury SP, Chattopadhyay D, Roy S.* (2001) J Biol Chem. 276, 30948-55.https://doi.org/10.1074/jbc.M011705200 A "master" in base unpairing during isomerization of a promoter upon RNA polymerase binding. Lim, HM., Lee, HJ., Roy, S., & Adhya, S. (2001) Proc Natl Acad Sci (U S A), 98, 14849-52. https://doi.org/10.1073/pnas.261517398 Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, CW., & Appella, E. (2000) J Biol Chem, 275, 9278-83. https://doi.org/10.1074/jbc.275.13.9278 Interaction of Gal repressor with inducer and operator: induction of gal transcription from repressor-bound DNA. Chatterjee, S., Zhou, YN., Roy, S., & Adhya, S. (1997) Proc Natl Acad Sci (USA), 94 2957-2962. https://doi.org/10.1073/pnas.94.7.2957 A fluorescence anisotropy study of tetramer-dimer equilibrium of l-repressor and its implications for function.

== Biosynthesis == In Aspergillus fumigatus, the enzymes needed for gliotoxin biosynthesis are encoded in 13 genes within the gli gene cluster. When this gene cluster is activated, these enzymes mediate the production of gliotoxin from serine and phenylalanine residues. The function of some genes contained within the gli gene cluster remain to be elucidated. Enzymes Involved in Biosynthesis (in order of activity)

== Background == Microtox was developed by Azur Environmental (formerly Microbics Corporation) in 1979 as a cost-effective alternative to toxicity tests available at the time. Prior to Microtox, the majority of toxicity tests available for water specifically focused on fish and daphnids. Since its inception, Microtox has become a standard method for testing the toxicity of water as well as other substrates such as soils and sediments. In recent years the Microtox technology and name have undergone various different ownerships. In 2011, Microtox and related technologies was acquired by Modern Water from Strategic Diagnostics Incorporated (SDIX) for approximately $4.5 million. Prior to SDIX, Microtox was owned by its original developers Azur Environmental. Microtox utilizes a bioluminescent bacteria (Allivibrio fischeri) to determine the toxicity of a particular substance and/or substrate. During cellular metabolism, these bacteria naturally emit light as a part of cellular respiration, which can be measured as luminescence. When exposed to toxic substances, a decrease in luminescence can be observed and percent change in luminescence can be directly correlated to toxicity. Allivibrio fischeri were specifically chosen, as these bacteria could be preserved by freeze-drying to increase shelf life and use. Both solid phase (soils and sediment) and aqueous acute toxicity testing (described below) can be conducted using this technology.

Sources: en.wikipedia.org

Reference notes

=== Wound repair === As a major component of the extracellular matrix, hyaluronic acid has a key role in tissue regeneration, inflammation response, and angiogenesis, which are phases of wound repair. As of 2023, however, reviews of its effect on healing for chronic wounds including burns, diabetic foot ulcers or surgical skin repairs show either insufficient evidence or only limited positive clinical research evidence. There is also some limited evidence to suggest that hyaluronic acid may be beneficial for ulcer healing and may help to a small degree with pain control. Hyaluronic acid combines with water and swells to form a gel, making it useful in skin treatments as a dermal filler for facial wrinkles; its effect lasts for about 6 to 12 months, and treatment has regulatory approval from the US Food and Drug Administration.

Administration a 100 mg/m2 dose over a one-hour infusion gave a mean total body clearance of 21 L/h/m2 and a mean steady state volume of distribution of 73.8 L/m2 or 123 L based on the mean BSA (body surface area) of 1.68 m2. Area under the plasma concentration-time curve had a mean value of 2.8 mg.h/L. The Cmax of docetaxel was found to be 4.15 ± 1.35 mg/L. Increased dose resulted in a linear increase of the area under the concentration-time curve and so it is concluded that dose is directly proportional to plasma concentration.

Willes (1963), former president of the Federal Reserve Bank of Minneapolis, CEO and Publisher of Los Angeles Times and Deseret Management Corporation Harry Saal (1963), co-founder of Network General Corporation, developer of the Sniffer Steven Clifford (1964), former CEO of King Broadcasting Company and National Mobile Television Arthur Cutler (1965), restaurateur, founder of Carmine's, Ollie's, and owner of Murray's Sturgeon Shop Ed Goodgold (1965), music industry executive and former manager of Sha Na Na, coined the term "trivia" Michael Gould (1966), former CEO of Bloomingdale's Julian Geiger (1967), former CEO of Aéropostale and current CEO of Crumbs Bake Shop Richard Sackler (1967), billionaire chairman and president of Purdue Pharma known for the development of Oxycontin Denny Greene (1971), former executive at Columbia Pictures, professor at University of Dayton School of Law, and member of Sha Na Na Mark E. Kingdon (1971), hedge fund manager, president of Kingdon Capital Management Philip L. Milstein (1971), former chairman and CEO of Emigrant Savings Bank, son of billionaire real estate developer Seymour Milstein Christopher M. Jeffries (1972), real estate developer, former husband of Princess Yasmin Aga Khan Marc Porat (1972), entrepreneur in information technology and sustainable materials; co-founder of General Magic John R. Eckel Jr. (1973), founder, CEO and chairman of Copano Energy Finbarr O'Neill (1973), former CEO of J.D. Power Fred Seibert (1973), TV producer and first creative director of MTV Robert B.

== Work in wound healing == Bale was part of the original team that established a unique wound healing service in the Wound Healing Research Unit, based at the University of Wales College of Medicine. She has written a range of books and articles on wound care. She is a founder member of the Wound Care Society (1985); the European Wound Management Association; (1991); the Journal of Wound Care (1992); the European Pressure Ulcer Advisory Panel (1996).

Sources: en.wikipedia.org

Frequently asked questions

What is GHK-Cu?

It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.

Where does the GHK sequence come from?

The tripeptide was first isolated from human plasma and has also been reported in saliva and urine. Plasma levels appear to decline with age in some small studies. Those observations rest on limited sample sizes.

Is GHK-Cu an approved drug?

It is not authorized as a systemic medicine in most countries. Cosmetic preparations list it as an ingredient rather than an active pharmaceutical substance. Legal status therefore differs by jurisdiction.

What is the difference between GHK and GHK-Cu?

GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.

Network